NY-AMERICAN-EXPRESS
21.3.2022 14:02:44 CET | Business Wire | Press release
American Express (NYSE:AXP) released the American Express Travel: 2022 Global Travel Trends Report 1 today, which shows people are looking forward to more trips than last year and planning to spend more or the same on travel in 2022 compared to a typical pre-pandemic year. The report, based on data from the United States, Australia, Canada, Mexico, Japan, India and the United Kingdom, reveals consumers are traveling to see the people and places they love, celebrate important life events, embark on wish list trips, experience in-person events, and to seek greater wellness and self-care. In Q4 2021, global Card Member bookings made through American Express Travel were up 24% compared to 2019 and have continued to strengthen in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005163/en/
“The pandemic has made all of us, including travelers, assess what is truly important,” said Audrey Hendley, President of American Express Travel. “The Global Travel Trends Report shows that tourists are making up for lost time and being thoughtful about who they travel with, the places they visit, the brands they support, and how they spend their money as the travel industry moves forward.”
Top insights from the American Express Travel: 2022 Global Travel Trends Report1 include:
- The world is ready to travel: 74% of respondents agree they are willing to book a trip for 2022 even if they might have to cancel or modify it later1 . This is up from 56% last year2 .
- Spending on travel is outpacing pre-pandemic levels : 86% of consumers expect to spend more or the same on travel in 2022 compared to a typical pre-pandemic year1 .
- Tourists want to travel more frequently: 62% of respondents plan on taking 2-4 trips in 2022 and 76% of respondents agree they plan to travel more with family in 2022 than they did in 2021.
- Tourists are seeking out brands that prioritize supporting local communities: 81% of respondents want to visit destinations where they can immerse themselves in the local culture and want the money they spend while traveling to go back to the local community.
- Dream destinations are becoming a reality: 55% of respondents want to book a once-in-a-lifetime vacation this year; especially true for Millennials (67%) and Gen Z (65%).
- As entertainment returns so do trips tied to in-person events: 56% of respondents stated they held off on traveling for major entertainment events last year but have plans to return to these types of events this year.
As travel momentum continues to grow, American Express Travel offers exclusive access and value, unique programs and benefits, and access to best-in-class travel expertise through American Express Travel Consultants who back Card Members with any type of trip.
The full American Express Travel: 2022 Global Travel Trends Report can be found here .
1 Survey Methodology: This Amex Trendex online poll was conducted by Morning Consult between February 3- 11th, 2022 among a national sample of 2,000 US and 1,000 travelers in Australia, Canada, India, Japan, Mexico, the UK, and the US who have a household income of at least $70K and defined as adults who typically travel by air at least once a year. Results from each market’s survey have a margin of error of plus or minus 3 percentage points.
2 Survey Methodology: This Amex Trendex online poll was conducted by Morning Consult between January 15-24, 2021 among a national sample of 1,000 travelers in Australia, Canada, India, Japan, Mexico and the U.K., and 2,000 in the U.S. $70k+ USD household income (HHI) equivalent in Australia, Canada, Japan, the U.K. and the U.S., $50k+ USD equivalent HHI in Mexico, and $20k+ USD equivalent household income in India. Travelers defined as adults who traveled by air at least once in 2019. Results have a margin of error of plus or minus 2 percentage points in the U.S.; plus or minus 3 percentage points in the other countries.
ABOUT AMERICAN EXPRESS
American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress , instagram.com/americanexpress , linkedin.com/company/american-express , twitter.com/americanexpress , and youtube.com/americanexpress .
Key links to products, services and corporate responsibility information: personal cards , business cards , travel services , gift cards , prepaid cards , merchant services , Accertify , Kabbage , Resy , corporate card , business travel , diversity and inclusion , corporate responsibility and Environmental, Social, and Governance reports .
Location: Global
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005163/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom